<p>Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterised by excessive keratinocyte proliferation and immune dysregulation. This results in thick, scaly plaques that negatively affect patients’ quality of life. Conventional treatment options such as topical agents, systemic drugs, and phototherapy are often limited by poor skin penetration, systemic side effects, and inconsistent patient adherence. This review aims to evaluate the therapeutic potential of nanoemulsion-based drug delivery systems as an emerging and more effective strategy for treating psoriasis. A comprehensive analysis of recent in vitro, in vivo, and clinical studies was performed. Key aspects reviewed include drug solubility, skin permeation, anti-inflammatory effects, patient compliance, and safety profiles of nanoemulsion-based formulations. Nanoemulsion significantly enhanced drug solubility and skin penetration and allowed for controlled drug release. In preclinical studies, these formulations reduced epidermal thickness, inflammatory markers, and lesion severity. Pilot clinical trials demonstrated improved Psoriasis Area and Severity Index (PASI) scores and greater patient satisfaction, with minimal reported side effects compared to conventional treatments. Nanoemulsion-based drug delivery systems represent a novel and promising therapeutic approach for managing psoriasis. Whilst formulation complexity and regulatory challenges remain, the evidence supports their potential to overcome many limitations of traditional therapies. Further large-scale, long-term clinical studies are essential to validate their safety, efficacy, and suitability for clinical application.</p>